ADAPY — Adaptimmune Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.60m
- $10.22m
- $178.03m
Adaptimmune Therapeutics PLC reports results for the quarter ended in June - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 13 cents a share - Earnings Preview
Adaptimmune Therapeutics PLC expected to post a loss of 13 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-DXP Enterprises, Holley, Augmedix
U.S. STOCKS ON THE MOVE-Arlo Technologies, Old Republic, Clearmind Medicine
Adaptimmune Therapeutics PLC reports results for the quarter ended in March - Earnings Summary
Brief: Adaptimmune Therapeutics Reports Q1 Results
Adaptimmune rises on upbeat Q1 revenue
Adaptimmune Therapeutics PLC expected to post a loss of 15 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Adaptimmune, Blink Charging, Silver miners
Adaptimmune up on agreement with GSK for transfer of cell therapy programs
Brief: Adaptimmune Therapeutics & Gsk Entered Into Termination & Transfer Agreement - SEC Filing
SVB shock could have chilling effect on British biotech sector (updated)
SVB shock could have chilling effect on British biotech sector
TCR2 Therapeutics surges on Adaptimmune buyout
TCR2 Therapeutics surges on Adaptimmune buyout
Adaptimmune Therapeutics PLC reports results for the quarter ended in December - Earnings Summary
Brief: Adaptimmune Therapeutics Revenue For Q4 Was $11.0 Million
Brief: Adaptimmune & Tcr² Therapeutics Announce Strategic Combination